{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:32:43Z","timestamp":1793251963938,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154769","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:20:15Z","timestamp":1792682415000},"page":"154769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel anti-PD-1\/VEGF bispecific fusion protein with enhanced VEGF binding capacity and developability for synergistic immunotherapy"],"prefix":"10.1016","volume":"840","author":[{"given":"Dan","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunguang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoshuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingcheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusha","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0677-7748","authenticated-orcid":false,"given":"Huaizu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154769_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154769_bib2","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154769_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154769_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-022-00297-8","article-title":"Current insight into the regulation of PD-L1 in cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154769_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6173","article-title":"PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance","volume":"8","author":"van Gulijk","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2026.154769_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.754","article-title":"PD\u2010L1\/TIGIT bispecific antibody showed survival advantage in animal model","volume":"12","author":"Mu","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154769_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154769_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000524977","article-title":"Combination immunotherapy with Anti-PD-1\/PD-L1 antibody plus Anti-VEGF antibody may promote cytotoxic T lymphocyte infiltration in hepatocellular carcinoma, including in the noninflamed subclass","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.bbrc.2026.154769_bib9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154769_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bbrc.2026.154769_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2026.154769_bib12","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154769_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2026.154769_bib14","author":"Zhuo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154769_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154769_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154769_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3155","article-title":"A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors","volume":"38","author":"Coward","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154769_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/19420862.2017.1409319","article-title":"Elimination of tumor by CD47\/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses","volume":"10","author":"Liu","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.bbrc.2026.154769_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.778978","article-title":"A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154769_bib20","first-page":"189","article-title":"A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy","volume":"8","author":"Wang","year":"2025","journal-title":"Antib Ther"},{"key":"10.1016\/j.bbrc.2026.154769_bib21","article-title":"Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154769_bib22","article-title":"Design of a Fc-engineered tetravalent bispecific antibody targeting PD-1 and VEGF with cooperative biological effects","author":"Zhong","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154769_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154769_bib24","article-title":"Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing","volume":"14","author":"Li","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbrc.2026.154769_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.791","article-title":"HER2\/PD1 bispecific antibody in IgG4 subclass with superior anti\u2010tumour activities","volume":"12","author":"Chu","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbrc.2026.154769_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67002-9","article-title":"Albumin-neprilysin fusion protein: understanding stability using small angle X-ray scattering and molecular dynamic simulations","volume":"10","author":"Kulakova","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154769_bib27","doi-asserted-by":"crossref","unstructured":"Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem. Biol. 2:1004\u20131020. doi: 10.1039\/d1cb00067e.","DOI":"10.1039\/D1CB00067E"},{"key":"10.1016\/j.bbrc.2026.154769_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.xphs.2024.11.016","article-title":"Storage stability and solution binding affinity of an Fc-fusion mimetic","volume":"114","author":"Prikalkhoran","year":"2025","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2026.154769_bib29","doi-asserted-by":"crossref","unstructured":"Rahban M, Ahmad F, Piatyszek MA, Haertl\u00e9 T, Saso L, Saboury AA. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 13:35947\u201335963. doi: 10.1039\/d3ra06476j.","DOI":"10.1039\/D3RA06476J"},{"key":"10.1016\/j.bbrc.2026.154769_bib30","article-title":"High-concentration L-methionine as a potent antioxidant for oxidation resistance and stability enhancement in high-concentration antibody therapeutics","volume":"10","author":"Wang","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.bbrc.2026.154769_bib31","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/acs.jproteome.4c01006","article-title":"Machine learning-enhanced cerebrospinal fluid N-Glycome for the diagnosis and prognosis of primary central nervous system lymphoma","volume":"24","author":"Liu","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbrc.2026.154769_bib32","unstructured":"Kim M-R. A Novel Vascular Endothelial Growth factor-trap KP-VR2 with Enhanced Ligand Blocking."},{"key":"10.1016\/j.bbrc.2026.154769_bib33","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/jasms.4c00063","article-title":"Rapid mass spectrometry-based multiattribute method for glycation analysis with integrated afucosylation detection capability","volume":"35","author":"Xu","year":"2024","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.bbrc.2026.154769_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115018","article-title":"Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins","volume":"220","author":"Liu","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbrc.2026.154769_bib35","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2026.154769_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835454","article-title":"Accurate MHC motif deconvolution of immunopeptidomics data reveals a significant contribution of DRB3, 4 and 5 to the total DR immunopeptidome","volume":"13","author":"Kaabinejadian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154769_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-61779-465-0_14","article-title":"AGGRESCAN: method, application, and perspectives for drug design","volume":"819","author":"de Groot","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.154769_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2105-8-65","article-title":"AGGRESCAN: a server for the prediction and evaluation of \u201chot spots\u201d of aggregation in polypeptides","volume":"8","author":"Conchillo-Sol\u00e9","year":"2007","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.bbrc.2026.154769_bib39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/btpr.2444","article-title":"Evaluation of heavy chain C-terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cells","volume":"33","author":"Hu","year":"2017","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.bbrc.2026.154769_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/19420862.2019.1664365","article-title":"Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development","volume":"11","author":"Dumet","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.bbrc.2026.154769_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154769_bib42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/19420862.2016.1197443","article-title":"Acid-induced aggregation propensity of nivolumab is dependent on the Fc","volume":"8","author":"Liu","year":"2016","journal-title":"mAbs"},{"key":"10.1016\/j.bbrc.2026.154769_bib43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/btpr.2024","article-title":"Inactivation of viruses using novel protein A wash buffers","volume":"31","author":"Bolton","year":"2015","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.bbrc.2026.154769_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110116","article-title":"Biosimilar monoclonal antibodies: challenges and approaches towards formulation","volume":"366","author":"Goli","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bbrc.2026.154769_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbrc.2026.154769_bib46","article-title":"Improving product quality and productivity of an antibody-based biotherapeutic using inverted frustoconical shaking bioreactors","volume":"12","author":"Wang","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154769_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2019.460836","article-title":"Chromatographic behavior of bivalent bispecific antibodies on hydrophobic interaction chromatography columns","volume":"1617","author":"Kimerer","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.bbrc.2026.154769_bib48","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bbrc.2026.154769_bib49","article-title":"Identification, efficacy, and stability evaluation of succinimide modification with a high abundance in the framework region of golimumab","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Chem."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26015354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26015354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:00:45Z","timestamp":1793250045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26015354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S0006291X26015354"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154769","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel anti-PD-1\/VEGF bispecific fusion protein with enhanced VEGF binding capacity and developability for synergistic immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154769"}}